Compare Gilead Sciences, Inc. (GILD) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs H2O America — how do they compare? Gilead Sciences, Inc. trades at $136.55 (market cap $163.51B), while H2O America trades at $64.47 (market cap $2.62B). The key difference: Gilead Sciences, Inc. is far larger — about 62.4× H2O America's market cap, and H2O America pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| GILD | HTO | |
|---|---|---|
Market Cap | $163.51B | $2.62B |
Sector | Health | Technology |
52-Week High | $155.80 | $62.94 |
52-Week Low | $108.22 | $44.44 |
Enterprise Value | $178.05B | $4.34B |
Dividend Yield | 2.49% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
HTO trades at $63.94, up 1.59% with strong technical momentum as moving averages signal bullish sentiment. The stock shows solid fundamentals with 12.87% net income margin and consistent earnings beats in three of the last four quarters. Recent corporate actions include a $0.44 dividend payment scheduled for June 2026, while analyst consensus remains strongly positive with 80% buy ratings.
The outlook remains favorable given HTO's stable utility business model and projected EPS growth. Key risks include high capital expenditure requirements and sensitivity to regulatory rate changes. With the current price near analyst targets, further upside may depend on Q2 2026 earnings exceeding expectations when reported on July 27, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
